Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics

Yoshiyuki Suehara, Naobumi Tochigi, Daisuke Kubota, Kazutaka Kikuta, Robert Nakayama, Kunihiko Seki, Akihiko Yoshida, Hitoshi Ichikawa, Tadashi Hasegawa, Kazuo Kaneko, Hirokazu Chuman, Yasuo Beppu, Akira Kawai, Tadashi Kondo

研究成果: Article査読

26 被引用数 (Scopus)


We aimed to develop prognostic biomarkers for synovial sarcoma employing a proteomic approach. We examined the proteomic profile of synovial sarcoma using two-dimensional difference gel electrophoresis (2D-DIGE). We identified 20 protein spots whose intensity was statistically different (p < 0.01) between a group of eight patients who were alive and continuously disease-free for over five years and a group of five patients who died of the disease within two years post diagnosis. Mass spectrometric protein identification demonstrated that these 20 spots corresponded to 17 distinct gene products. Three of the 20 spots corresponded to secernin-1 and had higher intensity in the good prognosis group. The prognostic performance of secernin-1 was further examined immunohistochemically in 45 synovial sarcoma cases. The 5-year survival rate was 77.6% and 21.8% for patients with secernin-1 positive and negative primary tumors respectively (p = 0.0015). The metastasis-free survival was significantly higher in the patient group with high secernin-1 expression compared to that with low expression (p = 0.0012). Uni- and multivariate analyses revealed that secernin-1 expression was a powerful prognostic factor compared to other clinico-pathological parameters examined. These results indicate that secernin-1 may be used as a biomarker to predict the overall and metastasis-free survival in synovial sarcoma patients.

ジャーナルJournal of Proteomics
出版ステータスPublished - 2011 5 16

ASJC Scopus subject areas

  • 生物理学
  • 生化学


「Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。